Skip to main content

Table 3 Unadjusted and adjusted associations between nucleated red blood cells and mortality (n = 2569)

From: Nucleated red blood cells, critical illness survivors and postdischarge outcomes: a cohort study

 

Mortality odds ratio (95% CI)a

0/μl NRBCs

1–100/μl NRBCs

101–200/μl NRBCs

>200/μl NRBCs

30-day post discharge mortality

 Crude

1.00 (Referent)

2.34 (1.51—3.62)

4.21 (2.18—8.11)

5.47 (3.07—9.74)

 Adjustedb

1.00 (Referent)

2.02 (1.27—3.21)

3.66 (1.81—7.39)

4.64 (2.45—8.79)

 Adjustedc

1.00 (Referent)

1.85 (1.16—2.95)

3.06 (1.50—6.22)

3.51 (1.82—6.77)

 Adjustedd

1.00 (Referent)

1.86 (1.19—2.90)

2.90 (1.46—5.74)

3.66 (1.98—6.75)

90-day post discharge mortality

 Crude

1.00 (Referent)

2.10 (1.50—2.94)

2.98 (1.69—5.25)

4.44 (2.74—7.21)

 Adjustedb

1.00 (Referent)

1.77 (1.23—2.54)

2.51 (1.36—4.62)

3.72 (2.16—6.39)

 Adjustedc

1.00 (Referent)

1.67 (1.16—2.41)

2.19 (1.18—4.05)

3.05 (1.75—5.34)

 Adjustedd

1.00 (Referent)

1.65 (1.16—2.34)

2.03 (1.12—3.69)

2.99 (1.78—5.04)

  1. CI confidence interval, NRBC nucleated red blood cell
  2. aReferent in each case is absence of NRBCs
  3. bModel 1: estimates adjusted for age, gender, race, Deyo–Charlson index, type (surgical vs medical), sepsis and acute organ failure
  4. cModel 2: estimates adjusted for age, gender, race, Deyo-Charlson index, type (surgical vs medical), sepsis, acute organ failure, hematocrit < 30, leukemia or myelodysplastic syndrome
  5. dModel 3: estimates adjusted for gender and the Acute Organ Failure score